Strong Year For Cephalon, But An Uncertain Future Remains
This article was originally published in The Pink Sheet Daily
Executive SummaryThe specialty pharma has made plenty of acquisitions and is pursuing late-stage options, but the upcoming loss of its lead product to generic competition may not be filled by the risky pipeline.
You may also be interested in...
Despite the patent cliff, 2012 is one of the final years of blockbusters going generic, leaving the large generic companies to establish their place in the morphing market.